The Boston biotech founded by Harvard professor David Sinclair is testing whether cellular reprogramming can turn back the ...

Scientists at The University of Texas at Austin have developed a revolutionary gene-editing method using bacterial retrons ...

Seven years after the first gene-edited babies were revealed, biotech startup Manhattan Genomics is reviving the idea of ...

Biomedical engineer Nenad Bursac, standing, and postdoctoral associate Tianyu Wu image a heart tissue patch through a microscope at the Bursac lab at the Duke University Pratt School of Engineering.

Fractyl Health announced a first-in-human trial for RJVA-001, targeting T2D and obesity, pending regulatory approval by 2026. Fractyl Health, Inc. has announced the submission of the first module of ...

In 1962, a pediatric neurology resident at Columbia's Neurological Institute and his colleagues in the College of Physicians ...

A naturally occurring gene called Cyclin A2 (CCNA2), which turns off after birth in humans, can actually make new, functioning heart cells and help the heart repair itself from injury, including a ...

We are now in the second great wave of the genetic revolution, not defined by reading the human code of life, but by rewriting it.

The goal of gene therapy is to permanently cure hereditary diseases. One of the most promising technologies for this is the ...

RheumaGen, Inc., a cell and gene therapy company engineering a new class of therapeutics to cure common autoimmune diseases, today announced groundbreaking preclinical research that supports a nearly ...